Scinai Immunotherapeutics Ltd. · NASDAQ:SCNI
Scinai Immunotherapeutics — BiondVax Pharmaceuticals — Investor Presentation (April 2022)
26 slides from Scinai Immunotherapeutics's investor presentation, Apr 4, 2022
Slide 1: Analyst and Investor Webinar, April 4, 2022
Analyst and Investor Webinar| April 4, 2022
Slide 2: Forward-looking statements disclaimer
2 This communication is not a prospectus or offer of securities for subscription or sale in any jurisdiction. This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995 . Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “m
Slide 3: Speakers and Agenda
3 Amir Reichman BiondVax CEO Professor Dr. Matthias Dobbelstein University Medical Center Göttingen 3 S PEAKERS Recent Business updates (Amir) The Science of NanoAbs (Matthias) NanoAb pipeline potential and timeline (Amir) BiondVax’s inhouse manufacturing & financial highlights (Amir) Q&A A GENDA
Slide 4: Recent Business Updates
4 Pipeline development • COVID - 19 NanoAb development • Research collaboration agreement with Max Planck and UMG for development of a pipeline of NanoAbs • Tech Transfer started, equipment acquired, manufacturing process development, preparations for GMP process scale up. Financial Summary • EIB de
Slide 5: Collaboration with Max Planck & UMG
5 COLLABORATION WITH MAX PLANCK & UMG • World - class science & access to leading scientists • NanoAb platform for development of promising potent therapeutics • Patents covering NanoAbs & their manufacturing • R&D knowledge, capabilities • Biosafety level 3 lab BIONDVAX MAX PLANCK & UMG Capabilitie
Slide 6: COVID and beyond – the use of NanoAbs for therapy
COVID - 19 and beyond – the use of NanoAbs for therapy MATTHIAS DOBBELSTEIN INSTITUTE OF MOLECULAR ONCOLOGY
Slide 7: Entry of SARS-CoV-2: Virus Spike binds cellular receptor
Entry of SARS - CoV - 2: Virus - Spike binds cellular receptor https://www.helmholtz.de/newsroom/artikel/was - kommt - nach - omikron/
Slide 8: Neutralizing NanoAbs to prevent the entry of SARS-CoV-2
Neutralizing NanoAbs to prevent the entry of SARS - CoV - 2 https://www.helmholtz.de/newsroom/artikel/was - kommt - nach - omikron/
Slide 9: Single Domain Antibodies (NanoAbs, VHHs): Why NanoAbs?
SINGLE DOMAIN ANTIBODIES ( NanoAbs , VHHs) VL 1 CL 1 VH 1 CH 1 CH 2 CH 3 CH 2 CH 3 VH 1 VH 1 CH 1 CH 2 CH 3 CH 2 CH 3 VH 1 VH 1 Conventional Antibody (IgG) Heavy Chain Only Antibody Single Domain Antibody → „ nanoAb “ Dirk Görlich Why NanoAbs?
Slide 10: NanoAb libraries and strongest binders
VL 1 CL 1 VH 1 CH 1 CH 2 CH 3 CH 2 CH 3 VH 1 VH 1 Conventional Antibody (IgG) NanoAb Hybridoma clones Bacteriophages ~10 3 ~10 8 (100 million ) The libraries to choose from Strongest binders
Slide 11: Extreme anti-viral potency of COVID19 NanoAbs
Extreme anti - viral potency of COVID19 NanoAbs Infection, fluorescence imaging
Slide 12: Extreme virus-neutralizing potency explained by X-ray structure
Extreme virus - neutralizing potency explained by X - ray structure VHH Re5D06 RBD (surface representation) VHH Re5D06 RBD cartoon surface VHH Re5D06 RBD Frontal clashes with RBD - bound ACE2
Slide 13: Hamsters were protected against COVID-19 by NanoAbs
Hamsters were protected against COVID - 19 by NanoAbs Nanobodies inhaled or injected , challenge with SARS - CoV - 2, monitoring body weight Body weight 6 days post infection (% weight before infection )
Slide 14: Large-scale production in Pichia pastoris
L arge - Scale production in Pichia pastoris Batch fermentation: up to 9 g per liter culture → kg yields in a standard 1000 liter fermenter Re5D06 10 15 20 25 30 40 50 60 70 85 10 0 kDa 0.5 µl Supernatant
Slide 15: Highly thermostable NanoAbs
15 Highly thermostable nanoAbs For any clinical application, antibodies need to be stable enough to survive the lengthy process of production, purification as well as storage . Best predictor for being developable: thermostability.
Slide 16: Advantages of NanoAbs
16 Advantages of NanoAbs ‣ Choice from 10 8 library ‣ Extreme affinities ‣ Neutralizing receptor binding ‣ Extreme thermostability ‣ Rapid development ‣ Affordable production ‣ Flexible engineering to meet PK requirements
Slide 17: Thank You (research contributors)
MPI - NAT Dirk Görlich Thomas Güttler Metin Aksu UMG Matthias Dobbelstein Kim Stegmann Antje Dickmanns Priya Kumar Insel Riems Anne Balkema - Buschmann THANK YOU!
Slide 18: Agenda
18 Recent Business updates (Amir) The Science of NanoAbs (Matthias) > NanoAb pipeline potential and timeline (Amir) BiondVax’s inhouse manufacturing & financial highlights (Amir) Q&A A GENDA
Slide 19: COVID-19 market continues to grow
19 COVID - 19 MARKET CONTINUES TO GROW -- AUTHORED BY THE SCIENTIFIC LEADS OF OUR MAX PLANCK COLLABORATION (3) 4M cases 2M Initial waves Jan 2020 Jun Jan 2021 Jun Jan 2022 1 . New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMp2118468 . | 2. WHO “ SARS - CoV - 2 is unlikely
Slide 20: Creating an innovative NanoAb pipeline
20 CREATING AN INNOVATIVE NANOAB PIPELINE Extending from a promising COVID - 19 therapeutic… • Validated targets of existing mAb treatments • Short time to value generation, lower risk than mAbs • Large markets growing at attractive CAGRs COVID 19 Lead candidate demonstrating strong competitive edge
Slide 21: Market potential
21 €2.6B asthma €10.4B psoriasis €5.0B macular degeneration €4.5B psoriatic arthritis MARKET POTENTIAL INITIAL FOCUS * Sources: Datamonitor ; Fiercepharma ; L.E.K. research and analysis; 2020 $1.6B+ Projected COVID - 19 antibody market FUTURE DERISKED TARGETS CURRENT MARKET SIZES*
Slide 22: Key Upcoming Catalysts
22 22 K EY U PCOMING C ATALYSTS 2022 2023 • EIB debt restructuring definitive agreement signed • Proof of concept in - vivo for inhalation route of administration (COVID19 NanoAb ) in animals • Initiate development of additional NanoAbs toward future targets • Clinical trial results (Phase 1/2a) – C
Slide 23: BiondVax's GMP Manufacturing and R&D Facility
23 B IOND V AX ’ S GMP M ANUFACTURING AND R&D F ACILITY • Equipped to produce recombinant protein products such as NanoAb • Single - use equipment enables: - Adaptable manufacturing processes for entire NanoAb pipeline - Quicker lead times - Faster time - to - market for new products • Designed to m
Slide 24: Select Financials & Cap Table
24 SELECT FINANCIALS & CAP TABLE • $9.8M raised December 2021 • $17.5M cash as of December 31, 2021 • $3M estimated quarterly burn in 2022 • €24M European Investment Bank (EIB) loan payable in Dec 2027 • Government of Israel support CAP TABLE As of Dec. 31, 2021 ADS OUTSTANDING % Ordinary ADS 18,476
Slide 25: Significant Potential for Value Creation
SIGNIFICANT POTENTIAL FOR VALUE CREATION Well - positioned to bring innovative therapies to market with unique large pharma competencies Strategic collaboration with Max Planck Institute & UMG world - leading research organizations Targeting massive, validated addressable markets with a pipeline of
Slide 26: Thank You
26 T HANK YOU BIONDVAX.COM Contact: Joshua Phillipson, Investor Relations j.phillipson@biondvax.com +972.8.930.2529
BiondVax Pharmaceuticals — Investor Presentation (April 2022) on 6ix